B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+25.03%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.13B
AUM Growth
-$243M
(-7.2%)
Cap. Flow
-$918M
Cap. Flow
% of AUM
-29.36%
Top 10 Holdings %
Top 10 Hldgs %
37.92%
Holding
89
New
20
Increased
16
Reduced
29
Closed
16
Avg Time Held
1
year
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.4M |
| 2 |
Kodiak Sciences
KOD
|
+$42.4M |
| 3 |
BrightSpring Health Services
BTSG
|
+$40.1M |
| 4 |
Celldex Therapeutics
CLDX
|
+$33.4M |
| 5 |
Illumina
ILMN
|
+$31.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xenon Pharmaceuticals
XENE
|
+$74.8M |
| 2 |
Krystal Biotech
KRYS
|
+$67M |
| 3 |
CG Oncology
CGON
|
+$58.5M |
| 4 |
Apogee Therapeutics
APGE
|
+$54.4M |
| 5 |
Danaher
DHR
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.49% |
| 2 | Miscellaneous | 16.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Vera Therapeutics
VERA
$1.95B
| $39.7M | 1.27% |
784,742
+312,003
| +66% | +$11.1M |
2025 Q3
1 quarter
|
|
27
iRhythm Holdings
IRTC
$3.46B
| $38.6M | 1.23% |
217,345
-8,500
| -4% | -$1.51M |
2022 Q4
12 quarters
|
|
28
Transmedics
TMDX
$2.61B
| $38.4M | 1.23% |
315,341
-35,907
| -10% | -$4.51M |
2024 Q4
4 quarters
|
|
29
BioMarin Pharmaceuticals
BMRN
$10.7B
| $35.7M | 1.14% |
601,520
+73,520
| +14% | +$4M |
2025 Q3
1 quarter
|
|
|
30
Illumina
ILMN
$40.5B
| $35.4M | 1.13% |
+269,673
| New | +$31.7M |
2025 Q4
0 quarters
|
|
31
Kymera Therapeutics
KYMR
$8.94B
| $35.3M | 1.13% |
454,259
+177,567
| +64% | +$12M |
2025 Q3
1 quarter
|
|
32
Fulcrum Therapeutics
FULC
$281M
| $34.6M | 1.11% |
3,061,222
+2,841,734
| +1,295% | +$28.9M |
2025 Q3
1 quarter
|
|
33
Penumbra
PEN
$12.6B
| $34.2M | 1.1% |
110,152
-31,376
| -22% | -$8.67M |
2022 Q4
12 quarters
|
|
34
MBX Biosciences
MBX
$2.33B
| $32.1M | 1.03% |
+1,018,600
| New | +$24.7M |
2025 Q4
0 quarters
|
|
35
DELISTED
RAPT Therapeutics
RAPT
| $31.5M | 1.01% |
+929,694
| New | +$28.9M |
2025 Q4
0 quarters
|
|
36
CareDx
CDNA
$3.37B
| $29.9M | 0.96% |
1,585,220
-597,561
| -27% | -$10M |
2025 Q3
1 quarter
|
|
37
Dyne Therapeutics
DYN
$2.8B
| $28.9M | 0.92% |
1,478,329
-1,252,152
| -46% | -$23.7M |
2024 Q4
4 quarters
|
|
38
enGene Therapeutics
ENGN
$106M
| $28.3M | 0.9% |
3,131,319
+865,000
| +38% | +$6.93M |
2025 Q3
1 quarter
|
|
39
Legend Biotech
LEGN
$3.78B
| $28.2M | 0.9% |
1,298,142
-528,013
| -29% | -$15.1M |
2022 Q4
12 quarters
|
|
40
Maravai LifeSciences
MRVI
$974M
| $27.1M | 0.87% |
8,353,287
| – | – |
2023 Q2
10 quarters
|
|
|
41
Danaher
DHR
$158B
| $27.1M | 0.87% |
118,227
-191,112
| -62% | -$42M |
2025 Q1
3 quarters
|
|
42
argenx
ARGX
$51.9B
| $26.1M | 0.83% |
31,007
-45,084
| -59% | -$38.6M |
2023 Q4
8 quarters
|
|
43
Natera
NTRA
$57.2B
| $25.5M | 0.82% |
+111,500
| New | +$23.3M |
2025 Q4
0 quarters
|
|
44
Bright Minds Biosciences
DRUG
$489M
| $25.3M | 0.81% |
324,358
+20,673
| +7% | +$1.38M |
2025 Q3
1 quarter
|
|
45
DELISTED
Terns Pharmaceuticals
TERN
| $23.2M | 0.74% |
+575,321
| New | +$13.3M |
2025 Q4
0 quarters
|
|
46
Evolus
EOLS
$487M
| $20.6M | 0.66% |
+3,105,209
| New | +$21M |
2025 Q4
0 quarters
|
|
47
Biogen
BIIB
$34.3B
| $20.4M | 0.65% |
+115,700
| New | +$18.9M |
2025 Q4
0 quarters
|
|
48
OrthoPediatrics
KIDS
$574M
| $19.5M | 0.63% |
1,100,370
-7,400
| -0.7% | -$130K |
2022 Q4
12 quarters
|
|
49
Tectonic Therapeutic
TECX
$410M
| $19.3M | 0.62% |
927,524
+190,657
| +26% | +$3.54M |
2025 Q3
1 quarter
|
|
50
DELISTED
Ventyx Biosciences
VTYX
| $17.3M | 0.55% |
+1,920,255
| New | +$14.4M |
2025 Q4
0 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q4 2025 Portfolio in Review
As of Q4 2025, Braidwell held 89 positions worth $3.13B, down 7.2% from $3.37B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Braidwell withdrew a net $918M in Q4 2025, closing 16 positions and reducing 29 holdings. Its most notable exit was Globus Medical, an estimated $28.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier, followed by Miscellaneous.
Against the trend, Braidwell opened a new position in Centessa Pharmaceuticals worth $54.7M.
- Braidwell's largest Q4 2025 buy was Centessa Pharmaceuticals: 2,188,320 shares worth $54.7M.
- Braidwell added most to Celldex Therapeutics in Q4 2025, an estimated $33.4M increase.
- Braidwell's biggest Q4 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $74.8M.
- Braidwell fully exited Globus Medical in Q4 2025, selling an estimated $28.5M.
- Braidwell's ten largest holdings make up 38% of its $3.13B portfolio in Q4 2025.
- Braidwell opened 20 new positions and closed 16 in Q4 2025.
- Braidwell's portfolio value fell 7.2% quarter-over-quarter to $3.13B.
Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.